Guo H - Search Results

1

Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.

Long AW, Xu H, Santich BH, Guo H, Hoseini SS, de Stanchina E, Cheung NV. Long AW, et al. Among authors: guo h. J Hematol Oncol. 2024 Apr 23;17(1):20. doi: 10.1186/s13045-024-01538-5. J Hematol Oncol. 2024. PMID: 38650005 Free PMC article.

2

A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.

Hoseini SS, Guo H, Wu Z, Hatano MN, Cheung NV. Hoseini SS, et al. Among authors: guo h. Blood Adv. 2018 Jun 12;2(11):1250-1258. doi: 10.1182/bloodadvances.2017014373. Blood Adv. 2018. PMID: 29858209 Free PMC article.

3

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.

Hoseini SS, Espinosa-Cotton M, Guo HF, Cheung NV. Hoseini SS, et al. J Immunother Cancer. 2020 Nov;8(2):e001626. doi: 10.1136/jitc-2020-001626. J Immunother Cancer. 2020. PMID: 33239418 Free PMC article.

4

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

Hoseini SS, Vadlamudi M, Espinosa-Cotton M, Tran H, Feng Y, Guo HF, Xu H, Cheung I, Cheung NV. Hoseini SS, et al. Among authors: guo hf. J Immunother Cancer. 2021 May;9(5):e002509. doi: 10.1136/jitc-2021-002509. J Immunother Cancer. 2021. PMID: 34035113 Free PMC article.

5

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.

Lopez-Albaitero A, Xu H, Guo H, Wang L, Wu Z, Tran H, Chandarlapaty S, Scaltriti M, Janjigian Y, de Stanchina E, Cheung NK. Lopez-Albaitero A, et al. Among authors: guo h. Oncoimmunology. 2017 Mar 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017. Oncoimmunology. 2017. PMID: 28405494 Free PMC article.

6

Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.

Wu Z, Guo HF, Xu H, Cheung NV. Wu Z, et al. Among authors: guo hf. Mol Cancer Ther. 2018 Oct;17(10):2164-2175. doi: 10.1158/1535-7163.MCT-18-0026. Epub 2018 Aug 6. Mol Cancer Ther. 2018. PMID: 30082472 Free PMC article.

7

Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.

Santich BH, Park JA, Tran H, Guo HF, Huse M, Cheung NV. Santich BH, et al. Among authors: guo hf. Sci Transl Med. 2020 Mar 11;12(534):eaax1315. doi: 10.1126/scitranslmed.aax1315. Sci Transl Med. 2020. PMID: 32161106 Free PMC article.

8

Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses.

Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DB, Punzalan B, Pillarsetty NVK, Xu H, Guo HF, Monette S, Michel AO, Piersigilli A, Scheinberg DA, Ouerfelli O, Cheung NV, Larson SM. Cheal SM, et al. Among authors: guo hf. Theranostics. 2020 Sep 14;10(25):11359-11375. doi: 10.7150/thno.48810. eCollection 2020. Theranostics. 2020. PMID: 33052220 Free PMC article.

9

A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.

Xu H, Buhtoiarov IN, Guo H, Cheung NV. Xu H, et al. Among authors: guo h. Oncoimmunology. 2021 Mar 11;10(1):1893500. doi: 10.1080/2162402X.2021.1893500. Oncoimmunology. 2021. PMID: 33763293 Free PMC article.

10

Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody.

Nakajima M, Guo HF, Hoseini SS, Suzuki M, Xu H, Cheung NV. Nakajima M, et al. Among authors: guo hf. Pediatr Blood Cancer. 2021 Jul;68(7):e28971. doi: 10.1002/pbc.28971. Epub 2021 Apr 12. Pediatr Blood Cancer. 2021. PMID: 33844437 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19,723 results

Search Page